TrialSite News includes excerpts from Business Herald. It reports a range of new roxithromycin research initiatives worldwide. For example, according to research by Otago University, New Zealand, roxithromycin can be effective in treating myeloma, a cancer of plasma cells that usually arises in the bone marrow and is mainly associated with depletion of hemoglobin levels. The drug aids in the boosting hemoglobin levels, which suggests that the amount of myeloma in bone marrow has reduced.
Key market players in the global roxithromycin market include:
- Hetero Healthcare Ltd.
- Finecure Pharmaceuticals Ltd.
- Zhejiang Zhenyuan
- Pharmaceutical Co Ltd
- Johnson & Johnson Private Limited
- Hygeia Laboratories Inc.
- Galderma S.A
- Valeant Pharmaceutical International